Whitepaper: Indication based pricing – Widely advocated but not yet feasible

Find out how the notion of value based pricing methodologies are becoming more common place in pharmaceutical medicines pricing and how Indication-based pricing (IBP) has been proposed as a potential solution for any medicine that offers benefits across many different indications.

In this whitepaper we explore:

  • The concept of value and IBP in medicines pricing
  • Key medicines which have attempted an IBP style strategy
  • Observations of IBP in Germany and France
  • Challenges facing the adoption of IBP

Simply fill in the form below and we’ll send you a copy of the whitepaper.

Request your copy of the whitepaper

* indicates required